Karyopharm Therapeutics to Participate in Upcoming Investor Conferences
Aug 30, 2017 11:00 am UTC| Business
NEWTON, Mass., Aug. 30, 2017 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in the...
Bob Evans Reports First Quarter FY 2018 Results and Raises Guidance
Aug 30, 2017 11:00 am UTC| Business
First quarter net sales increase 27.1% to $109.3 million as compared to $85.9 million1 in the comparable period in fiscal 2017; net sales increased 11.1% excluding Pineland net sales and sales to Bob Evans Restaurants (now...
Xcerra Announces Fourth Quarter and Fiscal Year Results
Aug 30, 2017 11:00 am UTC| Business
Fourth Fiscal Quarter Notables: Fourth quarter sales of $126.9 million the highest in the company’s historyGAAP net income of $12.4 million or $0.23 per diluted shareNon-GAAP net income of $14.0 million or $0.25 per...
Merus to Participate in Two Investor Conferences in September 2017
Aug 30, 2017 11:00 am UTC| Business
UTRECHT, The Netherlands, Aug. 30, 2017 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,...
Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
Aug 30, 2017 11:00 am UTC| Business
HOUSTON, Aug. 30, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior...
Loxo Oncology to Present at Upcoming Investor Conferences
Aug 30, 2017 10:45 am UTC| Business
STAMFORD, Conn., Aug. 30, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced...
Epizyme to Participate in Upcoming Investor Conferences
Aug 30, 2017 10:30 am UTC| Business
CAMBRIDGE, Mass., Aug. 30, 2017 -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will participate in the following...